Deciphering the Immunomodulatory Function of GSN + Inflammatory Cancer‐Associated Fibroblasts in Renal Cell Carcinoma Immunotherapy: Insights From Pan‐Cancer Single‐Cell Landscape and Spatial Transcriptomics Analysis
Cell Proliferation · 2025-12 · 58 (12)
DOI: 10.1111/cpr.70062 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Proliferation, online erschienen am 15.05.2025. Verfasst von Shan Li und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Cancer-Associated Fibroblasts, Kidney Neoplasms, Immunotherapy. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Postdoctoral Science Foundation, Natural Science Foundation of Jiangsu Province, Natural Science Research Project of Higher Education Institutions in Jiangsu Province.
Abstract (Originalsprache)
The heterogeneity of cancer‐associated fibroblasts (CAFs) could affect the response to immune checkpoint inhibitor (ICI) therapy. However, limited studies have investigated the role of inflammatory CAFs (iCAFs) in ICI therapy using pan‐cancer single‐cell RNA sequencing (scRNA‐seq) and spatial transcriptomics sequencing (ST‐seq) analysis. We performed pan‐cancer scRNA‐seq and ST‐seq analyses to identify the subtype of GSN + iCAFs, exploring its spatial distribution characteristics in the context of ICI therapy. The pan‐cancer scRNA‐seq and bulk RNA‐seq data are incorporated to develop the Caf.Sig model, which predicts ICI response based on CAF gene signatures and machine learning approaches. Comprehensive scRNA‐seq analysis, along with in vivo and in vitro experiments, investigates the mechanisms by which GSN + iCAFs influence ICI efficacy. The Caf.Sig model demonstrates well performances in predicting ICI therapy response in pan‐cancer patients. A higher proportion of GSN + iCAFs is observed in ICI non‐responders compared to responders in the pan‐cancer landscape and clear cell renal cell carcinoma (ccRCC). Using real‐world immunotherapy data, the Caf.Sig model accurately predicts ICI response in pan‐cancer, potentially linked to interactions between GSN + iCAFs and CD8 + Tex cells. ST‐seq analysis confirms that interactions and cellular distances between GSN + iCAFs and CD8 + exhausted T (Tex) cells impact ICI efficacy. In a co‐culture system of primary CAFs, primary tumour cells and CD8 + T cells, downregulation of GSN on CAFs drives CD8 + T cells towards a dysfunctional state in ccRCC. In a subcutaneously tumour‐grafted mouse model, combining GSN overexpression with ICI treatment achieves optimal efficacy in ccRCC. Our study provides the Caf.Sig model as an outperforming approach for patient selection of ICI therapy, and advances our understanding of CAF biology and suggests potential therapeutic strategies for upregulating GSN in CAFs in cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
- Uro-Oncology Institute of Central South University, Changsha, Hunan, China.
- Department of Urology, Children's Hospital of Chongqing Medical University, Chongqing, China.
- Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China.
- Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China.
ORCID-Profile: Shan Li
Förderung
- China Postdoctoral Science Foundation
- Natural Science Foundation of Jiangsu Province
- Natural Science Research Project of Higher Education Institutions in Jiangsu Province
- Leading Innovative Talents in Changzhou
- Research Foundation of Guangzhou Women and Children's Medical Center for Clinical Doctor
- National Natural Science Foundation of China
- Medical Scientific Research Foundation of Guangdong Province of China
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Li, S., Zhou, X., Feng, H., Huang, K., Chen, M., Lin, M., Lin, H., Deng, Z., Chen, Y., Liao, W., Zhang, Z., Chen, J., Guan, B., Su, T., Feng, Z., Shu, G., Yu, A., Pan, Y., & Fu, L. (2025). Deciphering the Immunomodulatory Function of GSN + Inflammatory Cancer‐Associated Fibroblasts in Renal Cell Carcinoma Immunotherapy: Insights From Pan‐Cancer Single‐Cell Landscape and Spatial Transcriptomics Analysis. Cell Proliferation, 58(12). https://doi.org/10.1111/cpr.70062
Vancouver
Li S, Zhou X, Feng H, Huang K, Chen M, Lin M, et al. Deciphering the Immunomodulatory Function of GSN + Inflammatory Cancer‐Associated Fibroblasts in Renal Cell Carcinoma Immunotherapy: Insights From Pan‐Cancer Single‐Cell Landscape and Spatial Transcriptomics Analysis. Cell Proliferation. 2025;58(12). doi:10.1111/cpr.70062
BibTeX
@article{Li2025,
author = {Li, Shan and Zhou, Xinwei and Feng, Haoqian and Huang, Kangbo and Chen, Minyu and Lin, Mingjie and Lin, Hansen and Deng, Zebing and Chen, Yuhang and Liao, Wuyuan and Zhang, Zhengkun and Chen, Jinwei and Guan, Bohong and Su, Tian and Feng, Zihao and Shu, Guannan and Yu, Anze and Pan, Yihui and Fu, Liangmin},
title = {Deciphering the Immunomodulatory Function of GSN + Inflammatory Cancer‐Associated Fibroblasts in Renal Cell Carcinoma Immunotherapy: Insights From Pan‐Cancer Single‐Cell Landscape and Spatial Transcriptomics Analysis},
journal = {Cell Proliferation},
year = {2025},
volume = {58},
number = {12},
doi = {10.1111/cpr.70062}
}
EUVIMED